ERBB2 and breast carcinoma: In the in vivo study by Zhang et al. [36] using the same mechanism, emodin (40 mg/kg bw, i.p) was found to suppress tumor growth and prolong the survival of mice in mice carrying HER-2/neu-overexpressing human breast cancer cells (MDA-MB-361).